The historical rank and industry rank for Enorama Pharma AB's Days Payable or its related term are showing as below:
OSTO:ERMA'
s Days Payable Range Over the Past 10 Years
Min: 73.89 Med: 144.46 Max: 314.75
Current: 160.99
During the past 12 years, Enorama Pharma AB's highest Days Payable was 314.75. The lowest was 73.89. And the median was 144.46.
OSTO:ERMA's Days Payable is ranked better than 78.2% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs OSTO:ERMA: 160.99
Enorama Pharma AB's Days Payable
declined
from Mar. 2025 (28.31) to Mar. 2026 (0.00).
It may suggest that Enorama Pharma ABaccelerated paying its suppliers.
Enorama Pharma AB Days Payable Related Terms
Enorama Pharma AB Days Payable Historical Data
* Premium members only.
The historical data trend for Enorama Pharma AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ERMA vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enorama Pharma AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Enorama Pharma AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enorama Pharma AB (OSTO:ERMA) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Enorama Pharma AB and its competitors. Over the past decade, Enorama Pharma AB's Days Payable has ranged from 73.89 to 314.75. According to the industry distribution chart, Enorama Pharma AB ranks #201 out of 922 companies in the Drug Manufacturers industry, placing it in the top 21.8%.
Is Enorama Pharma AB's Days Payable too high?
Enorama Pharma AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 73.89 to a high of 314.75. Based on the distribution chart, Enorama Pharma AB ranks #201 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #201 out of 922 companies for Days Payable. This places Enorama Pharma AB in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.61. Historically, Enorama Pharma AB's own Days Payable has ranged from 73.89 to 314.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Enorama Pharma AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enorama Pharma AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.41, compared to a current price of kr0.30 — trading 27.8% below its estimated fair value. The current Days Payable is 0.00. Enorama Pharma AB's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?
Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued.
The current stock price of kr0.30 is trading 27.8% below its estimated GF Value™ of kr0.41.
GuruFocus considers Enorama Pharma AB to be Modestly Undervalued.
Key valuation signals for OSTO:ERMA:
Days Payable: 0.00
GF Value™: kr0.41 vs. price of kr0.30 (27.8% below fair value)
No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
29GF Score
Get the complete analysis for OSTO:ERMA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ERMA has been successfully added to your 
